论文部分内容阅读
目的分析胰岛素短期强化治疗初发2型糖尿病的临床效果。方法选取丰县人民医院内分泌科2015年3月—2016年3月收治的初发2型糖尿病患者66例,根据不同的治疗方法分为对照组(n=34)和研究组(n=32)。患者入院后均给予以常规对症治疗,对照组患者给予二甲双胍联合格列齐特口服治疗,研究组患者给予二甲双胍联合优泌林70/30治疗,两组患者均持续治疗14~90d。观察比较两组患者治疗前后相关临床指标(三酰甘油、胰岛素、糖化血红蛋白、胆固醇及空腹血糖)、胰岛素抵抗指数、胰岛素敏感指数及超氧化物歧化酶(SOD)及丙二醛(MDA)水平,并比较两组患者治疗期间不良反应发生情况。结果治疗前,两组患者三酰甘油、胰岛素、糖化血红蛋白、胆固醇及空腹血糖水平比较,差异无统计学意义(P>0.05);治疗后,研究组患者三酰甘油、胰岛素、糖化血红蛋白、胆固醇及空腹血糖水平低于对照组(P<0.05)。治疗前,两组患者胰岛素抵抗指数、胰岛素敏感指数比较,差异无统计学意义(P>0.05);治疗后,研究组患者胰岛素抵抗指数、胰岛素敏感指数低于对照组(P<0.05)。治疗前,两组患者SOD、MDA水平比较,差异无统计学意义(P>0.05);治疗后,研究组患者SOD水平高于对照组,MDA水平低于对照组(P<0.05)。研究组患者不良反应发生率低于对照组(P>0.05)。结论二甲双胍联合优泌林70/30治疗2型糖尿病可有效降低患者血脂、血糖及MDA水平,提高患者胰岛素抵抗性与敏感性,且安全性好。
Objective To analyze the clinical effect of short-term intensive insulin treatment of type 2 diabetes mellitus. Methods Sixty-six patients with newly diagnosed type 2 diabetes were enrolled in the Department of Endocrinology of Fengxian People’s Hospital from March 2015 to March 2016. The patients were divided into control group (n = 34) and study group (n = 32) according to different treatment methods. Patients were given conventional symptomatic treatment after admission, the control group were given metformin combined with gliclazide oral treatment, the study group were given metformin combined with excellent selin 70/30 treatment, both groups were sustained treatment of 14 ~ 90d. The clinical indexes (triglyceride, insulin, glycosylated hemoglobin, fasting blood glucose, fasting blood glucose), insulin resistance index, insulin sensitivity index, superoxide dismutase (SOD) and malondialdehyde (MDA) , And compared the incidence of adverse reactions between the two groups during treatment. Results Before treatment, there was no significant difference in triglyceride, insulin, glycosylated hemoglobin, cholesterol and fasting blood glucose between the two groups (P> 0.05). After treatment, triglyceride, insulin, glycosylated hemoglobin, cholesterol And fasting blood glucose level was lower than the control group (P <0.05). Before treatment, there was no significant difference in insulin resistance index and insulin sensitivity index between the two groups (P> 0.05). After treatment, insulin resistance index and insulin sensitivity index in the study group were lower than those in the control group (P <0.05). Before treatment, there was no significant difference in SOD and MDA levels between the two groups (P> 0.05). After treatment, SOD level in study group was higher than that in control group, and MDA level was lower than that in control group (P <0.05). The incidence of adverse reactions in study group was lower than that in control group (P> 0.05). Conclusions Metformin combined with ophthalmic sera 70/30 in treatment of type 2 diabetes mellitus can effectively reduce the level of blood lipids, blood glucose and MDA, and improve the insulin resistance and sensitivity of patients with good safety.